Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04627038 · ClinicalTrials.gov registry record · Phase 2
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
A Phase 2 study of Osteoarthritis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
- 20
- Study locations
NCT04627038: Completed Phase 2 study of Osteoarthritis, sponsored by Eli Lilly and Company.
NCT04627038 is a Phase 2 study of Osteoarthritis that has completed, run by Eli Lilly and Company. The registered enrollment target is 202 participants, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04627038, a Phase 2 study of Osteoarthritis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
Primary Outcome
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3556050
Study Locations (20)
Florida
- VIN-Julie Schwartzbard - Aventura
- Clinical Research of South Florida - Coral Gables
- Suncoast Research Group - Miami
- University of Miami Don Suffer Clinical Research Building - Miami
- New Horizon Research Center - Miami
- Renstar Medical Research - Ocala
- Synexus Clinical Research US, Inc - Orlando - Orlando
- Synexus Clinical Research - St. Petersburg - Pinellas Park
- Martin E. Hale M.D., P.A. - Plantation
- Synexus Clinical Research US, Inc. - The Villages
Arizona
- Synexus- Chandler - Chandler
- Synexus Clinical Research - Glendale - Glendale
- Alliance for Multispecialty Research - Clinical Research Consortium - Tempe
California
- Irvine Clinical Research - Irvine
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
Illinois
- Synexus Clinical Research - Chicago
- Northwestern University - Chicago
Alabama
- Simon Williamson Clinic - Birmingham
Connecticut
- CMR of Greater New Haven - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2020-11-12 |
| Est. Completion | 2021-10-21 |
| Phase | Phase 2 |
What the finished NCT04627038 record still lists
NCT04627038 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, below the 816-participant average among 135 other Osteoarthritis trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04627038 names 20 study sites across 6 states, led by Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT04627038 about?
NCT04627038 is a clinical study titled "Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis". This study is being done to test the safety and efficacy of LY3556050 for the treatment of osteoarthritis pain. This trial is part of the chronic pain master protocol, H0P-MC-CPMP (NCT05986292), which is a protocol to accelerate the development of new treatments for chronic pain.
What is the current status of trial NCT04627038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2020-11-12. Estimated completion is 2021-10-21.
What conditions does trial NCT04627038 study?
This clinical trial studies the following conditions: Osteoarthritis.
What interventions are being tested in trial NCT04627038?
The interventions under investigation include: Placebo (DRUG), LY3556050 (DRUG).
Who is sponsoring clinical trial NCT04627038?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04627038 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04627038's enrollment target sits among peer trials
202 55th of 135 higher than 81 of 135 other Osteoarthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder
RECRUITING · Phase 2
-
Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip
RECRUITING · Phase 2
-
Platelet Rich Plasma Injections In Young And Old Human Subjects
RECRUITING · Phase 2
-
A Mobile Intervention to Reduce Pain and Improve Health-III
RECRUITING · Phase 2
-
An Study to Evaluate Safety and Tolerability of OA-SYS in Subjects With Moderate to Severe Osteoarthritis of the Knee Joint
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI